



August 08, 2019

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub : Outcome of the Board Meeting in terms of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Ref : HealthCare Global Enterprises Limited (“the Company”)
(NSE Scrip Code: HCG/ BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, the 8th August 2019, *inter alia*, has considered and approved the following agenda:

1. Unaudited Financial Results of the Company, both Standalone and Consolidated (Limited Review), for the quarter ended June 30, 2019 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and
2. Issue and allotment of 8,000 (Eight Thousand) equity shares of the Company of Rs. 10 each, upon exercise of Employee Stock Options under Employee Stock Option Scheme, 2014 of the Company.

We enclose herewith the Unaudited Financial Results of the Company (Standalone and Consolidated) for the quarter ended June 30, 2019 together with the Limited Review Report by the Statutory Auditors.

The results are also being uploaded on the Company’s website at www.hcgel.com.

The Meeting of the Board concluded at 4.15 P.M.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Dr. B. S. Ajaikumar
Chairman & CEO

Encl: as above

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1, B Block, 2nd Floor
Inner Ring Road, Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly standalone financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (“the Company”) for the quarter ended 30 June 2019 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the quarter ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.



Limited review report on unaudited quarterly standalone financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (continued)

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No. 101248W/W-100022

Amit Somani

Amit Somani
Partner
Membership No.060154
UDIN:19060154AAAAAN5978

Place: Bengaluru
Date: 8 August 2019

HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 June 2019	Preceding quarter ended 31 March 2019	Corresponding quarter ended in the previous year 30 June 2018	Previous year ended 31 March 2019
		Unaudited	(Refer note 2)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	17,061	16,561	15,401	64,050
	(b) Income from government grant	28	32	15	93
	(c) Other income	245	681	170	1,255
	Total income	17,334	17,274	15,586	65,398
2	Expenses				
	(a) Purchases of medical and non-medical items	3,615	3,674	3,893	15,254
	(b) Changes in inventories	115	133	(18)	77
	(c) Employee benefits expense	3,530	3,443	3,031	13,032
	(d) Finance costs	1,879	1,166	974	4,781
	(e) Depreciation and amortisation expense	1,772	1,264	1,064	4,717
	(f) Medical consultancy charges	3,325	3,042	2,814	11,965
	(g) Other expenses	3,439	3,942	3,313	14,315
	Total expenses	17,675	16,664	15,071	64,141
3	Profit/(loss) before tax (1-2)	(341)	610	515	1,257
4	Tax expense				
	- Current tax expense/ (credit)	-	(437)	118	(283)
	- Deferred tax expense/ (credit)	(140)	744	66	815
	Total tax expense/ (credit)	(140)	307	184	532
5	Profit/ (loss) for the period / year (3-4)	(201)	303	331	725
6	Other comprehensive income / (expense)				
	(i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	12	-	12
	- Income tax effect on (i) above	-	(4)	-	(4)
	(ii) Items that will be reclassified to profit or loss				
	- Effective portion of gain/ (loss) on hedging instruments in a cash flow hedge	100	(24)	-	(643)
	- Income tax on (ii) above	(35)	8	-	223
	Other comprehensive income/ (expense) for the period / year, net of tax	65	(8)	-	(412)
7	Total comprehensive income/(expense) for the period / year (5+6)	(136)	295	331	313
8	Paid-up equity share capital (Face value of Rs. 10 each)	8,863	8,792	8,786	8,792
9	Reserves, i.e., 'Other equity'				55,680
10	Earnings/(loss) per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	(0.23)	0.35	0.38	0.83
	(b) Diluted	(0.23)	0.35	0.38	0.82
	See accompanying notes to the Standalone Financial Results				



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019

Notes:

1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 30 June 2019, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 8 August 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.


The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditor is unqualified.

2 The figures for preceding quarter ended 31 March 2019 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review.

3 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

4 Effective 1 April 2019, the Company adopted Ind AS 116 "Leases" using modified retrospective approach and accordingly, the Company has not restated comparative information. The effect of adoption has resulted in decrease in rent included in 'Other expenses' of Rs. 589 lakhs, increase in interest expense included in 'Finance costs' of Rs 515 lakhs and increase in depreciation and amortization expense of Rs. 450 lakhs for the quarter ended 30 June 2019.

For and on behalf of the Board of Directors


Dr. B. S. Ajakumar
Chairman and CEO

Bengaluru, 08 August 2019



B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1, B Block, 2nd Floor
Inner Ring Road, Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive loss of its associate and a joint venture for the quarter ended 30 June 2019 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



B S R & Co. LLP**Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (continued)**

4. The Statement includes the results of the following entities:

SI. No.	Name of the Entity	Subsidiary/ Associate/ Joint Venture	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited (formerly known as MIMS HCG Oncology Private Limited)	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group)	Associate	Mauritius
15	Strand Life Sciences Private Limited	Joint Venture	India

5. Attention is drawn to the fact that the figures for the quarter ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

B S R & Co. LLP

Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (continued)

7. We did not review the financial information/ financial results of a subsidiary and a step down subsidiary included in the Statement, whose financial information/ financial results reflect total revenues (including other income) of Rs 24 lakhs, total net income after tax of Rs 4 lakhs and total comprehensive loss of Rs 73 lakhs, for the quarter ended 30 June 2019, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group's share of net loss after tax of Rs. 367 lakhs and total comprehensive loss of Rs 367 lakhs for the quarter ended 30 June 2019, as considered in the Statement, in respect of an associate and a joint venture, whose financial information/ financial results have not been reviewed by us. These financial information/ financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, an associate and a joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No. 101248W/W-100022

Amit Somani

Amit Somani
Partner

Membership No.060154
UDIN : 19060154AAAAAO8388

Place: Bengaluru
Date: 8 August 2019

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended	Preceding quarter	Corresponding	Previous year
		30 June 2019	ended 31 March 2019	quarter ended in the previous year 30 June 2018	ended 31 March 2019
		Unaudited	(Refer note 2)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	26,810	25,710	22,598	97,602
	(b) Income from government grant	78	82	58	265
	(c) Other income	130	323	94	741
	Total income	27,018	26,115	22,750	98,608
2	Expenses				
	(a) Purchases of medical and non-medical items	5,741	5,683	5,079	22,149
	(b) Changes in inventories	103	27	(102)	(285)
	(c) Employee benefits expense	5,133	4,877	4,228	18,452
	(d) Finance costs	3,119	1,556	1,754	6,991
	(e) Depreciation and amortisation expense	3,412	2,280	1,973	8,509
	(f) Medical consultancy charges	6,102	5,560	4,795	21,138
	(g) Other expenses	5,324	6,425	5,601	23,894
	Total expenses	28,934	26,408	23,328	100,848
3	Loss before share of loss of an associate / joint venture and tax (1-2)	(1,916)	(293)	(578)	(2,240)
4	Share of loss of an associate / joint venture, net of taxes	(367)	(525)	(192)	(1,098)
5	Loss before tax (3+4)	(2,283)	(818)	(770)	(3,338)
6	Tax expense				
	- Current tax expense/ (credit)	46	(326)	124	(110)
	- Deferred tax expense/ (credit)	(270)	596	(261)	(140)
	Total tax expense/ (credit)	(224)	270	(137)	(250)
7	Loss for the period / year (5-6)	(2,059)	(1,088)	(633)	(3,088)
8	Other comprehensive income / (expense)				
	(i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	30	-	30
	- Exchange differences on translation of financial statements of foreign operations	(77)	12	-	114
	- Income tax effect on above	-	(9)	-	(9)
	(ii) Items that will be reclassified to profit or loss				
	- Effective portion of gain/ (loss) on hedging instruments in a cash flow hedge	100	(20)	-	(643)
	- Income tax on (ii) above	(35)	9	-	225
	Other comprehensive income / (expense) for the period / year, net of taxes	(12)	22	-	(283)
9	Total comprehensive loss for the period / year (7+8)	(2,071)	(1,066)	(633)	(3,371)
	Loss for the period / year attributable to:				
	Equity holders of the Company	(1,802)	(872)	(341)	(2,480)
	Non-controlling interests	(257)	(216)	(292)	(608)
	Other comprehensive income / (expense) for the period / year attributable to				
	Equity holders of the Company	(12)	18	-	(287)
	Non-controlling interests	-	4	-	4
	Total comprehensive loss for the period / year attributable to				
	Equity holders of the Company	(1,814)	(854)	(341)	(2,767)
	Non-controlling interests	(257)	(212)	(292)	(604)
10	Paid-up equity share capital (Face value of Rs. 10 each)	8,863	8,792	8,786	8,792
11	Reserves, i.e., 'Other equity'				38,873
12	Loss per share (face value of Rs. 10 each)				
	(a) Basic	(2.05)	(0.99)	(0.39)	(2.82)
	(b) Diluted	(2.05)	(0.99)	(0.39)	(2.82)
	See accompanying notes to the Consolidated Financial Results				



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2019

Notes:

1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter ended 30 June 2019, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 8 August 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditor is unqualified.

2 The figures for preceding quarter ended 31 March 2019 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review.

3 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

4 Effective 1 April 2019, the Group adopted Ind AS 116 "Leases" using modified retrospective approach and accordingly, the Group has not restated comparative information. The effect of adoption has resulted in decrease in rent included in 'Other expenses' of Rs. 1,440 lakhs, increase in interest expense included in 'Finance costs' of Rs 1,245 lakhs and increase in 'depreciation and amortization expense of Rs. 1,030 lakhs for the quarter ended 30 June 2019.

For and on behalf of the Board of Directors


Dr. B. S. Ajankumar
Chairman and CEO

Bengaluru, 08 August 2019

